126 results
S-3
MREO
Mereo Biopharma Group Plc
15 May 24
Shelf registration
4:49pm
-LD.
Our strategy is to selectively acquire and develop product candidates for rare diseases that have already received significant investment from … in March 2015, we have successfully executed on this strategy by acquiring six clinical-stage product candidates of which four were in rare diseases
10-Q
2024 Q1
MREO
Mereo Biopharma Group Plc
15 May 24
Quarterly report
4:19pm
in this Quarterly Report, including information with respect to our plans and strategy for our business, includes forward-looking statements … Track designation for the treatment of AATD-LD.
Our strategy is to selectively acquire and develop product candidates for rare diseases that have
DEF 14A
MREO
Mereo Biopharma Group Plc
24 Apr 24
Definitive proxy
7:30am
on our Board of Directors since November 2022. Mr. Yoskowitz is Chief Executive Officer of Evozyne, Inc. Previously he served as EVP and Chief Strategy … initiatives within the Pfizer portfolio. Prior to Pfizer, he served as SVP, Strategy and Corporate Development at Hospira and was a member
10-K
2023 FY
EX-10.30
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
and information, including study designs and protocols, reagents and biological methodology, any strategy for the prosecution, maintenance, enforcement and defense
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
U.S. Orphan Drug Designation for the treatment of AATD and Fast Track designation for the treatment of AATD-LD.
Our strategy is to selectively acquire … on this strategy by acquiring six clinical-stage product candidates of which four were in rare diseases and oncology. Four of our six clinical-stage
6-K
EX-99.1
39yi4lzmingo7v rvev
17 Oct 23
Current report (foreign)
7:01am
6-K
EX-99.2
4a4dl3
7 Sep 23
Current report (foreign)
7:37am
6-K
EX-99.1
ayvgb9fz86i9h8 eyab
6 Jul 23
Ultragenyx Announces First Patients Dosed in Phase 3 Program
8:05am
6-K
EX-99.1
tov7innrdifamkm
5 Jun 23
Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit
4:37pm
6-K
EX-99.2
7ji7vm1c8r9em6
2 Nov 22
Current report (foreign)
4:17pm
6-K
EX-99.2
sp1df uv3c45qc
28 Oct 22
Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management
7:11am
6-K
EX-99.1
ylgmetospoij6xjay
21 Oct 22
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
7:06am
6-K
EX-99.2
ie0kv4cdcqyfup0j4
21 Oct 22
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
7:06am
6-K
EX-99.1
zut oxkc7
18 Oct 22
Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value
7:07am
6-K
EX-99.1
h8ups 0rdk
3 Oct 22
Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders
5:43pm
6-K
EX-99.1
vdl0akcvp3dw7a dlrs
12 Sep 22
Data support further evaluation of PVR, CD226, and TIGIT as potential biomarkers of enrichment for etigilimab plus anti-PD1 therapy
8:17am
6-K
EX-99.1
47mmomol 0sd6syh
31 Aug 22
Letter Reiterates Mereo’s Updated Strategic Plan to Maximize Value for All Shareholders and Corrects Rubric’s Assumptions
7:57am
6-K
EX-99.1
7n9vx0
22 Aug 22
Notifies Rubric of Certain Deficiencies in its Notice Purporting to Call a General Meeting of Shareholders
4:06pm
6-K
EX-99.1
0d1n1gnewvk
2 Jun 22
Mereo Also Updates Capital Allocation and Portfolio Prioritization Plan
9:07am
6-K
js4p8zof
17 May 22
Mereo BioPharma Announces Appointment of Dr. Abdul Mullick to Board of Directors
8:19am